Actinium Pharmaceuticals, Inc. (ATNM) Form 8-K — May 29, 2026
Actinium Pharmaceuticals (ATNM) received a notice from NYSE American indicating it is not in compliance with continued listing standards due to stockholders' equity of $2.3 million, below the required $4.0 million threshold, and net losses in its last five fiscal years. The company must submit a compliance plan by June 26, 2026, to regain compliance by November 27, 2027. Failure to submit an acceptable plan or meet the deadline will trigger delisting proceedings. Shares will continue to trade on NYSE American with a '.BC' indicator denoting below-compliance status.
Key figures
- Required Equity
- 4000000
- Stockholders Equity
- 2300000
- Compliance Deadline
- 2027-11-27
- Plan Submission Deadline
- 2026-06-26
- Fiscal Years With Net Losses
- 5
Price after filing
Close on the filing date to close N calendar days later (from $1.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.